Spondyloarthritis & psoriatic arthritis
Uveitis in psoriatic arthritis: study of 406 patients in a single university center and literature review
Authors' conclusion
The prevalence of uveitis in patients with PsA was about 5%. The pattern was similar to that observed in ax-SpA. Uveitis was associated with a worse quality of life and greater functional disability. The uveitis exposure adjusted incidence rate decreased with anti-TNFα monoclonal antibodies and increased with ETN and SECU.
Study context
- Population
- Psoriatic arthritis (PsA) patients (CASPAR criteria) from a single referral hospital (46.3±12.3 years)
- Participants
- 406 patients
- Exposure
- PsA with uveitis vs PsA without uveitis
- Uveitisn = 20
- Outcome
- Frequency and clinical features of uveitis
Methodological detailssingle-centre, literature review
- Single-centre
- Literature review
Main finding
As reported in the abstract
Uveitis
4.9%
20
- Anterior
- 80%
- Unilateral
- 80%
- Recurrent
- 50%
Observational data: associations, not effects.
Further findings
HLA-B27 prevalence
P < 0.0001
Sacroiliitis on MRI
P = 0.027
Ocular surface pathology
P = 0.021
Median
| Outcome | Uveitis | Without uveitis | P value |
|---|---|---|---|
| PsA Impact of Disease Score | 5.9 (range 2.1–6.8) | 1.25 (range 0.0–3.0) | P = 0.001 |
| BASFI | 4 (range 1.6–5) | 1.0 (range 0.0–3.5) | P = 0.01 |
Exposure adjusted incidence rate of uveitis (episodes/100 patients-year), before vs after biological treatment
- Anti-TNFα monoclonal antibodies: before vs after
- 56.3 vs 9.4
- Etanercept (ETN): before vs after
- 6.03 vs 24.2
- Secukinumab (SECU): before vs after
- 0 vs 50
- ETN and SECU: including only one patient treated in each
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →